Repare Therapeutics shares jumped in premarket trading after the company agreed to sell its polymerase theta ATPase inhibitor to Gilead Sciences for up to $30 million. Shares were 18% higher at $2.57 ...

The FDA declined to approve its relacorilant. The regulator wrote that it lacked sufficient evidence from the biotech about the drug's effectiveness. That morning, Corcept announced it had received a ...

The average one-year price target for Pasithea Therapeutics (NasdaqCM:KTTA) has been revised to $3.06 / share. This is an increase of 50.00% from the prior estimate of $2.04 dated August 1, 2023. The ...

Amy Bachrodt, SVP, Finance at Maze Therapeutics, Inc. (NASDAQ:MAZE), sold 15,000 shares of common stock on December 29 and 30, 2025, for approximately $606,173. The sales occurred at weighted average ...

Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration Repare Therapeutics Inc. (“Repare” or the “Company”) ...

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced a definitive asset purchase agreement for Gilead Sciences, Inc. to ...

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)-- Repare Therapeutics Inc. (RPTX), a clinical-stage precision oncology company, today announced a definitive asset purchase agreement for Gilead Sciences, ...

Investing.com - Truist Securities has reiterated a Buy rating and $200.00 price target on Axsome Therapeutics (NASDAQ:AXSM) following the acceptance of the company’s supplemental New Drug Application ...

The U.S. Equal Employment Opportunity Commission is suing Wendy's, alleging disability and age discrimination. The lawsuit alleges Wendy's fired a district manager in his 50s after he took approved ...

Workplace tension does not always come from poor performance or personality clashes. In some cases, it grows when a manager feels uneasy about an employee’s competence or future potential. Instead of ...

) has been revised to $28.76 / share. This is an increase of 11.68% from the prior estimate of $25.76 dated December 3, 2025. The price target is an average of many targets provided by analysts. The ...